Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,819 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Management of Guttate Psoriasis: A Systematic Review.
Zhou T, Koussiouris J, Kim L, et al. · J Cutan Med Surg · 2024Systematic Review
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW, Puig L, Joshi A, et al. · JAMA Dermatol · 2020Comparative Study, Research Support, Non-U.S. Gov't
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB, Blauvelt A, Poulin Y, et al. · Br J Dermatol · 2021Clinical Trial, Phase III, Multicenter Study
- Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Papp KA, Lebwohl MG, Puig L, et al. · Am J Clin Dermatol · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256ߙweeks (LIMMitless trial).
Strober B, Bachelez H, Crowley J, et al. · J Eur Acad Dermatol Venereol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, et al. · Br J Dermatol · 2020Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
Tsai TF, Tada Y, Kung C, et al. · J Dermatol · 2024Comparative Study, Systematic Review
- Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R, Krueger JG, Glatt S, et al. · Br J Dermatol · 2022Clinical Trial, Phase II, Multicenter Study
- Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial.
Zhang J, Zhou C, Miao G, et al. · J Am Acad Dermatol · 2026Randomized Controlled Trial, Clinical Trial, Phase II
- Association between psoriasis and atrial fibrillation: A Systematic review and meta-analysis.
Jain H, Odat RM, Goyal A, et al. · Curr Probl Cardiol · 2024Systematic Review, Meta-Analysis
- Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Iversen L, Conrad C, Eidsmo L, et al. · J Eur Acad Dermatol Venereol · 2023Randomized Controlled Trial, Multicenter Study
- Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.
Prajapati VH, Seyger MMB, Wilsmann-Theis D, et al. · Br J Dermatol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis.
Malhotra A, Shafiq N, Rajagopalan S, et al. · Evid Based Med · 2012Meta-Analysis, Systematic Review
- Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Huang IH, Yu CL, Tai CC, et al. · J Dtsch Dermatol Ges · 2022Systematic Review, Network Meta-Analysis
- Frequency of phototherapy for treating psoriasis: a systematic review.
Damiani G, Pacifico A, Chu S, et al. · Ital J Dermatol Venerol · 2022Systematic Review
- Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials.
Igarashi A, Tsuji G, Fukasawa S, et al. · J Dermatol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
Xu S, Zhang X, Pan M, et al. · Int Immunopharmacol · 2019Meta-Analysis, Systematic Review
- Predictors of Topical Use in Psoriasis Patients in the REFINE Study.
Gooderham MJ, Poulin-Costello M, Shelton J, et al. · J Cutan Med Surg · 2016Clinical Trial, Phase III, Multicenter Study
- Lasers for the treatment of psoriasis: a systematic review.
Heidemeyer K, Kulac M, Sechi A, et al. · Expert Rev Clin Immunol · 2023Systematic Review
- Transcriptomic meta-analysis identifies core molecular pathways in plaque psoriasis.
Torres-Moral T, Riera-Monroig J, Tell-Martí G, et al. · J Eur Acad Dermatol Venereol · 2026Meta-Analysis, Systematic Review
- Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
Aljefri YE, Ghaddaf AA, Alkhunani TA, et al. · Dermatol Ther · 2022Meta-Analysis, Systematic Review
- Narrowband-Ultraviolet B Phototherapy for Psoriasis Treatment in Skin of Color: A Systematic Review and Meta-Analysis.
Hauptman M, El Othmani A, Pazhyanur S, et al. · Photodermatol Photoimmunol Photomed · 2025Systematic Review, Meta-Analysis
- Laser treatment of psoriasis.
Katugampola GA, Rees AM, Lanigan SW · Br J Dermatol · 1995Clinical Trial, Controlled Clinical Trial
- A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.
Zhang C, Yan K, Diao Q, et al. · J Am Acad Dermatol · 2022Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis.
Advani S, Raja A, Giraldo T, et al. · Clin Exp Dermatol · 2026Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.